Literature DB >> 8610140

Activation of CD4+ T lymphocytes form interleukin 2-deficient mice by costimulatory B7 molecules.

Z Razi-Wolf1, G A Höllander, H Reiser.   

Abstract

Interleukin 2 (IL-2)-deficient (IL-2-/-) mice develop hemolytic anemia and chronic inflammatory bowel disease. Importantly, the induction of disease in IL-2-deficient mice is critically dependent on CD4+ T cells. We have studied the requirements of T cells from IL-2-deficient mice for costimulation with B7 antigens. Stable B7-1 or B7-2 chinese hamster ovary (CHO) cell transfectants could synergize with anti-CD3 monoclonal antibody (mAb) to induce the proliferation of CD4+ T cells from IL-2-/- mutant mice. Further mechanistic studies established that B7-induced activation resulted in surface expression of the alpha chain of the IL-2 receptor. B7-induced proliferation occurred independently of IL-4 and was largely independent of the common gamma chain of the IL-2, IL-4, IL-7, IL-9, and IL-15 receptors. Finally, anti-B7-2 but not anti-B7-1 mAb was able to inhibit the activation of IL-2-/- T cells induced by anti-CD3 mAb in the presence of syngeneic antigen-presenting cells. The results of our experiments indicate that IL-2-/- CD4+ T cells remain responsive to B7 stimulation and raise the possibility that B7 antagonists have a role in the prevention/treatment of inflammatory bowel disease.

Entities:  

Mesh:

Substances:

Year:  1996        PMID: 8610140      PMCID: PMC39732          DOI: 10.1073/pnas.93.7.2903

Source DB:  PubMed          Journal:  Proc Natl Acad Sci U S A        ISSN: 0027-8424            Impact factor:   11.205


  42 in total

Review 1.  Pivotal role of the B7:CD28 pathway in transplantation tolerance and tumor immunity.

Authors:  E C Guinan; J G Gribben; V A Boussiotis; G J Freeman; L M Nadler
Journal:  Blood       Date:  1994-11-15       Impact factor: 22.113

Review 2.  T cells in inflammatory bowel disease: protective and pathogenic roles.

Authors:  F Powrie
Journal:  Immunity       Date:  1995-08       Impact factor: 31.745

3.  CD28 costimulation can promote T cell survival by enhancing the expression of Bcl-XL.

Authors:  L H Boise; A J Minn; P J Noel; C H June; M A Accavitti; T Lindsten; C B Thompson
Journal:  Immunity       Date:  1995-07       Impact factor: 31.745

4.  Defective lymphoid development in mice lacking expression of the common cytokine receptor gamma chain.

Authors:  X Cao; E W Shores; J Hu-Li; M R Anver; B L Kelsall; S M Russell; J Drago; M Noguchi; A Grinberg; E T Bloom
Journal:  Immunity       Date:  1995-03       Impact factor: 31.745

5.  CTLA4Ig treatment ameliorates the lethality of murine graft-versus-host disease across major histocompatibility complex barriers.

Authors:  P M Wallace; J S Johnson; J F MacMaster; K A Kennedy; P Gladstone; P S Linsley
Journal:  Transplantation       Date:  1994-09-15       Impact factor: 4.939

6.  Evidence that CD4+, but not CD8+ T cells are responsible for murine interleukin-2-deficient colitis.

Authors:  S J Simpson; E Mizoguchi; D Allen; A K Bhan; C Terhorst
Journal:  Eur J Immunol       Date:  1995-09       Impact factor: 5.532

7.  In vivo blockade of CD28/CTLA4: B7/BB1 interaction with CTLA4-Ig reduces lethal murine graft-versus-host disease across the major histocompatibility complex barrier in mice.

Authors:  B R Blazar; P A Taylor; P S Linsley; D A Vallera
Journal:  Blood       Date:  1994-06-15       Impact factor: 22.113

8.  Human B7-1 (CD80) and B7-2 (CD86) bind with similar avidities but distinct kinetics to CD28 and CTLA-4 receptors.

Authors:  P S Linsley; J L Greene; W Brady; J Bajorath; J A Ledbetter; R Peach
Journal:  Immunity       Date:  1994-12       Impact factor: 31.745

9.  B7-1 and B7-2 do not deliver identical costimulatory signals, since B7-2 but not B7-1 preferentially costimulates the initial production of IL-4.

Authors:  G J Freeman; V A Boussiotis; A Anumanthan; G M Bernstein; X Y Ke; P D Rennert; G S Gray; J G Gribben; L M Nadler
Journal:  Immunity       Date:  1995-05       Impact factor: 31.745

10.  Naive versus memory CD4 T cell response to antigen. Memory cells are less dependent on accessory cell costimulation and can respond to many antigen-presenting cell types including resting B cells.

Authors:  M Croft; L M Bradley; S L Swain
Journal:  J Immunol       Date:  1994-03-15       Impact factor: 5.422

View more
  5 in total

1.  Th1-type responses mediate spontaneous ileitis in a novel murine model of Crohn's disease.

Authors:  M M Kosiewicz; C C Nast; A Krishnan; J Rivera-Nieves; C A Moskaluk; S Matsumoto; K Kozaiwa; F Cominelli
Journal:  J Clin Invest       Date:  2001-03       Impact factor: 14.808

2.  The role of costimulatory molecules CD80 and CD86 and IFNgamma in the pathogenesis of ulcerative colitis.

Authors:  Marco Scarpa; Roubik Behboo; Imerio Angriman; Barbara Termini; Michela Barollo; Cesare Ruffolo; Lino Polese; Renata D'Incà; Giacomo Carlo Sturniolo; Davide Francesco D'Amico
Journal:  Dig Dis Sci       Date:  2004 Nov-Dec       Impact factor: 3.199

3.  Cell cycle progression following naive T cell activation is independent of Jak3/common gamma-chain cytokine signals.

Authors:  Min Shi; Tsung H Lin; Kenneth C Appell; Leslie J Berg
Journal:  J Immunol       Date:  2009-09-04       Impact factor: 5.422

4.  Anti-IL-2 treatment impairs the expansion of T(reg) cell population during acute malaria and enhances the Th1 cell response at the chronic disease.

Authors:  Cláudia A Zago; Karina R Bortoluci; Luiz R Sardinha; Fernando D Pretel; Sheyla I Castillo-Méndez; Ana Paula Freitas do Rosário; Meire I Hiyane; Sandra M Muxel; Sérgio M Rodriguez-Málaga; Ises A Abrahamsohn; José M Álvarez; Maria Regina D'Império Lima
Journal:  PLoS One       Date:  2012-01-17       Impact factor: 3.240

5.  A natural immunological adjuvant enhances T cell clonal expansion through a CD28-dependent, interleukin (IL)-2-independent mechanism.

Authors:  A Khoruts; A Mondino; K A Pape; S L Reiner; M K Jenkins
Journal:  J Exp Med       Date:  1998-01-19       Impact factor: 14.307

  5 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.